Vericel (NASDAQ:VCEL) Upgraded at Zacks Research

Zacks Research upgraded shares of Vericel (NASDAQ:VCEL) from a hold rating to a strong-buy rating in a research report report published on Tuesday,Zacks.com reports.

Other equities analysts also recently issued research reports about the company. Truist Financial decreased their target price on Vericel from $46.00 to $41.00 and set a “buy” rating for the company in a report on Wednesday. Weiss Ratings restated a “sell (d+)” rating on shares of Vericel in a report on Wednesday, October 8th. Canaccord Genuity Group decreased their target price on Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a report on Friday, August 1st. BTIG Research cut Vericel from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 17th. Finally, Stephens restated an “overweight” rating and issued a $67.00 target price on shares of Vericel in a research note on Monday, June 16th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $58.40.

Vericel Price Performance

Shares of VCEL stock opened at $34.75 on Tuesday. The stock has a market capitalization of $1.75 billion, a PE ratio of 289.61 and a beta of 1.39. Vericel has a 1-year low of $29.24 and a 1-year high of $63.00. The business has a 50-day moving average of $33.71 and a 200 day moving average of $38.34.

Vericel (NASDAQ:VCEL) last posted its earnings results on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.03. The firm had revenue of $63.24 million for the quarter, compared to analysts’ expectations of $64.61 million. Vericel had a return on equity of 2.47% and a net margin of 2.85%.The business’s revenue was up 20.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.10) earnings per share. Analysts anticipate that Vericel will post 0.14 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. increased its stake in Vericel by 13.7% during the second quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 353 shares during the last quarter. State of Wyoming increased its stake in Vericel by 3.8% during the first quarter. State of Wyoming now owns 10,428 shares of the biotechnology company’s stock worth $465,000 after acquiring an additional 381 shares during the last quarter. California State Teachers Retirement System increased its stake in Vericel by 0.8% during the second quarter. California State Teachers Retirement System now owns 45,404 shares of the biotechnology company’s stock worth $1,932,000 after acquiring an additional 382 shares during the last quarter. Maryland State Retirement & Pension System increased its stake in Vericel by 2.8% during the second quarter. Maryland State Retirement & Pension System now owns 14,795 shares of the biotechnology company’s stock worth $630,000 after acquiring an additional 408 shares during the last quarter. Finally, Scholtz & Company LLC increased its stake in Vericel by 0.9% during the second quarter. Scholtz & Company LLC now owns 50,573 shares of the biotechnology company’s stock worth $2,152,000 after acquiring an additional 454 shares during the last quarter.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.